FDA panel reviews first mRNA-based flu vaccine from Moderna

Washington: U.S. health advisers are reviewing a first-of-its-kind influenza vaccine developed using mRNA technology, the same scientific approach that played a key role in addressing the COVID-19 pandemic. The vaccine, developed by Moderna and named mFlusiva, is currently under consideration by the Food and Drug Administration (FDA) for use in adults aged 50 and above. New approach to flu vaccines The FDA advisory committee meeting marks a significant step towards potential approval of the vaccine ahead of the upcoming winter flu season. Unlike traditional flu vaccines, mRNA-based vaccines can be produced more quickly, which experts say could allow faster responses to changes in influenza strains. Clinical trial results According to trial data involving around 40,000 participants aged 50 and older, the vaccine reduced flu cases by approximately 27 percent compared to a standard flu vaccine currently in use. The FDA’s preliminary review of the data indicated no major safety concerns. Moderna is seeking full approval for individuals aged 50 to 64, along with conditional use for those aged 65 and older while further studies continue. Debate over effectiveness Despite promising results, the application has faced scrutiny. Earlier this year, a senior FDA official questioned whether the vaccine should have been tested against a high-dose flu vaccine specifically recommended for older adults, rather than a standard-dose comparator. Moderna responded by noting that the study design had been previously cleared by regulators and provided additional data suggesting comparable immune responses to high-dose vaccines. Challenges and next steps The advisory panel is also reviewing additional studies, including research on how well the vaccine stimulates antibodies in older populations. However, the FDA has noted that more data may be needed for very frail patients and individuals with weakened immune systems. Public health importance Influenza continues to pose significant health risks, causing tens of thousands of deaths annually in the United States, with older adults among the most vulnerable. While multiple vaccines are already available — including specific formulations for seniors — the introduction of mRNA technology could reshape how seasonal vaccines are developed and deployed. The advisory committee’s recommendations will inform the FDA’s final decision on whether to approve the vaccine. If authorised, it would mark the first mRNA flu vaccine available to the public, representing a potential advancement in both vaccine technology and pandemic preparedness strategies.